肾康注射液治疗早期糖尿病肾病的临床观察

Clinical Observation of Shenkang Injection in the Treatment of Early Diabetic Nephropathy

目的观察肾康注射液治疗早期糖尿病肾病的临床疗效。方法选取2013年7月至2015年4月收治的150例早期糖尿病肾病患者,随机分为治疗组与对照组各75例。对照组给予西医常规综合性治疗,主要包括糖尿病教育、运动、优质低蛋白饮食0.6~0.8 g/(kg·d)及胰岛素控制血糖;治疗组在对照组基础上加用肾康注射液。观察治疗前后的中医证候积分、空腹血糖(GLU)、餐后2h血糖、糖化血红蛋白(Hb A1c)、24小时尿蛋白定量(24 h-UTP)、尿微量白蛋白的变化。结果治疗后治疗组总有效率91.3%,对照组总有效率72.6%,两组比较,差异有统计学意义(P<0.01)。两组治疗后FBG、餐后2h血糖、Hb A1c的结果与治疗前比较,差异有统计学意义(P<0.01)。治疗组治疗后TG、TC与治疗前比较,差异有统计学意义(P<0.01),而对照组TG、TC与治疗前比较,差异无统计学意义(P>0.05)。两组治疗后24 h尿蛋白定量及尿微量白蛋白与治疗前比较,指标均明显下降,差异有统计学意义(P<0.01);且治疗组明显优于对照组,两组比较,差异有统计学意义(P<0.01)。结论肾康注射液能明显改善早期糖尿病肾病患者的各项指标,延缓糖尿病肾病的发展,值得临床推广应用。

Objective To observe the clinical therapeutic effect of shenkang injection on early diabetic nephropathy. Methods From July 2013 to April 2015,150 patients of early diabetic nephropathy were randomized into a treatment group and a control group,75 cases in each one. In the control group,the conventional comprehensive treatment was used,including the education on diabetes,exercise,the diet of high-quality protein0. 6 to 0. 8 g/( kg·d) and blood glucose control with insulin. In the treatment group,on the basis of the treatment as the control group,shenkang injection was added. Before and after treatment,TCM syndrome score,fasting blood glucose( FBG),2 h postprandial blood glucose( 2 h- FBG),glycosylated hemoglobin( Hb A1c),24 h urinary protein( 24 h- UTP) and microalmiuria( MAU) were observed. Results After treatment,the total effective rate was 91. 3% in the treatment group and was 72. 6% in the control group,indicating the significant difference( P < 0. 01). The differences in FBG,2h- FBG and Hb A1 c were significant before and after treatment in the two groups( P < 0. 01). In the treatment group,TG and TC after treatment were different significantly as compared with those before treatment( P < 0. 01). The differences in TG and TC were not significant before and after treatment in the control group( P > 0. 05). In the two groups,24 h-UTP and MAU after treatment were reduced apparently as compared with those before treatment,indicating the significant differences( P < 0. 01). The results in the treatment group were apparently better than those in the control group,indicating the significant difference( P < 0. 01). Conclusion Shenkang injection improves apparently the indexes in the patients of early diabetic nephropathy. It retards the development of diabetic nephropathy and deserves to be promoted in the clinical application.